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ABSTRACT
Introduction: Educational brochures are an
important tool for communicating risk to
health-care professionals. It is important to
evaluate the impact of any risk minimization
tool to understand the effectiveness of the
strategy. The objective of this study was to
assess the effectiveness (i.e., respondents’
awareness and understanding of the
communication) of a targeted educational
brochure distributed to health-care
professionals (HCPs) as a risk minimization
strategy for the communication of new rare
and important adverse events (AEs).
Methods: A prospective, non-interventional,
online survey was performed following
distribution of a specifically designed brochure
highlighting new and important adverse events
to a targeted HCP population, consisting of
known users of the target medicine, as
represented by a commercial database.
Predefined multiple-choice survey questions
assessed overall HCP awareness of the
brochure and understanding and retention of
information in those HCPs who reported
receiving the brochure.
Results: The educational brochure was sent to a
total of 565 HCPs; 121 (21.4%) responded to the
survey. The majority of respondents (95.0%)
had previously prescribed or dispensed the
target medicine. In all, 88 (72.7%) respondents
said they had received the educational
brochure, of whom 95.5% stated they had at
least scanned the main points. More
participants who had received the brochure
(86.4% to 96.6%) answered the five individual
survey questions correctly compared with those
who did not (51.5% to 97.0%); this was
significant for four out of five questions
(P B 0.005). Significantly more HCPs who
received the brochure achieved the predefined
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pass rate (at least four of five questions answered
correctly) compared with HCPs who did not
receive the brochure (93.2% vs 57.6%,
respectively; P = 0.000003).
Conclusions: Distribution of targeted
educational brochures may be an effective risk
minimization strategy to raise HCP awareness of
new rare and important AEs; educational
brochures may also be an effective channel for
sharing information on how these AEs can be
best managed and on the importance and
means of reporting AEs.
Funding: Celgene Pty Ltd, Melbourne,
Australia.
Keywords: Abraxane; Australia; Brochure;
Education; Health-care professionals;
Nab-paclitaxel; Risk management plans; Risk
minimization
INTRODUCTION
Dissemination of important or newly identified
clinical safety information to health-care
professionals (HCPs) is a key factor in
improving patient management and
outcomes, and additional risk minimization
measures are often required for specific
medicines to ensure that the benefits of the
products outweigh the risks. However, while it
is important to evaluate the impact of any risk
minimization tool to understand the
effectiveness of the strategy, guidance and
methods for evaluating these measures are
constantly evolving [1]. The effectiveness of
routine risk communication and risk
management delivered via the prescribing
information for a medicine has been
challenged for reasons relating to increasing
complexity, poor design and presentation, and
a lack of clarity [2]. This may be particularly
relevant to oncology products, where the
information about safety is often not only
extensive and complex, but vital.
Health-care professionals are exposed to a
vast range of information on medicines via
traditional printed materials (prescribing
information, product monographs,
publications in peer-reviewed journals,
guidelines) and numerous other sources
(educational campaigns and programs,
specialist Internet sites, marketing material
from pharmaceutical companies). This means
that keeping HCPs up to date and fully
informed about clinically important new
safety information associated with a particular
medicine can be challenging. Additional
educational tools, like HCP-targeted brochures,
may be an effective way of communicating
important information to HCPs in specific
therapeutic areas. Printed educational
materials (delivered by either traditional mail
or in an email-friendly digital format) are widely
used to disseminate information. Printed
materials offer many benefits that make them
well suited to the often rapidly changing
knowledge base and recommendations for
certain types of medicines—they are familiar,
accessible, inexpensive, and convenient to use
and, as such, have the potential to provide an
effective method for disseminating information
to HCPs [3]. In addition, printed materials have
been shown to have a small beneficial effect on
professional practice outcome compared to no
intervention [3].
To determine whether such materials could
be an effective way of minimizing safety risks
associated with an individual medicine, we
investigated the impact of the distribution of
an educational brochure (supplemental
materials: educational brochure) targeting
relevant HCPs in Australia; in this case, the
brochure was focused on awareness of new rare
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and important adverse events (AEs) associated
with the use of nanoparticle albumin-bound
paclitaxel [nab-paclitaxel; Abraxane;
Specialised Therapeutics Australia Pty Ltd
(STA), Kew East, Victoria, Australia]. The
educational brochure was distributed on behalf
of the sponsor (Abraxis BioScience Australia Pty
Ltd, an indirect subsidiary of Celgene
Corporation) in response to a request from the
Australian Government Department of Health
Therapeutics Goods Administration (TGA) to
implement an additional risk minimization
measure.
In Australia, nab-paclitaxel was first
approved by the TGA for the treatment of
metastatic carcinoma of the breast following
failure to respond to anthracycline therapy, and
was more recently approved for non-small cell
lung cancer and metastatic adenocarcinoma of
the pancreas. Three new rare and important
safety concerns (cranial nerve palsies,
cardiotoxicity, and Stevens–Johnson
syndrome/toxic epidermal necrolysis) were
identified from post-marketing surveillance of
nab-paclitaxel AE reports, and were
subsequently included in the nab-paclitaxel
prescribing information and the risk
management plan. In line with their
increasing focus on the post-approval safety
profile of medicines in the clinical setting, the
TGA recommended enhanced risk
minimization activities for these safety
concerns. As part of these activities, the
sponsor and the TGA agreed that an
educational brochure should be disseminated
to specialist oncologists and pharmacists. This
brochure was designed to raise HCP awareness
of three new rare and important AEs and show
how they can be best managed—emphasis was
placed on the importance of reporting these
events, and on providing information on where
to report such events if encountered. To
determine the effectiveness of the educational
brochure as a method of additional risk
minimization, a survey (supplemental
materials: survey) of the HCPs who had been
sent the brochure was conducted; questions
were constructed to assess coverage, awareness,




This was a prospective, non-interventional,
cross-sectional study. The TGA was consulted
throughout the protocol development process.
The HCP brochure distribution and subsequent
survey were designed to be deployed to
approximately 600 HCPs comprising medical
oncologists, oncology pharmacists, and
directors of pharmacy as listed in a database
maintained by STA. The STA database consists
of medical oncologists and oncology
pharmacists known to STA through
commercial activities and includes all known
users of nab-paclitaxel in Australia. As such, the
database provided a highly targeted group of
HCPs who used, prescribed, and/or dispensed
the target medicine.
A two-page HCP brochure entitled
‘‘Abraxane: Understanding Rare Important Side
Effects’’ was first prepared and published in Q3,
2012, and initially distributed by sales
representatives during face-to-face visits with
HCPs. On March 1, 2013, hard copies of the
brochure were posted to approximately 574
HCPs in Australia (medical oncologists,
oncology pharmacists, and directors of
pharmacy). On November 1, 2013, an updated
brochure, which included new indications for
non-small cell lung cancer and pancreatic
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adenocarcinoma, was sent via email exclusively
to HCPs newly identified since the March 1,
2013 distribution. The final distribution of this
HCP brochure was via email to 574 HCPs on
September 24, 2014, together with a link to the
Abraxane product information (current at the
time of the survey). As part of the final
distribution, the HCPs were informed that the
brochure formed part of the risk minimization
strategy for nab-paclitaxel and were given
advance warning that a survey would be sent
in approximately 1 week to assess their
understanding of the information provided in
the brochure.
Survey Design and Deployment
The survey was an online survey consisting of
five initial multiple-choice questions (Part 1)
which collected data on the job role and
location (state) of the HCPs and their prior
experience with nab-paclitaxel, and assessed
whether the HCPs had received and read the
educational brochure. In Part 2 of the survey,
the respondents’ recall of facts included in the
educational brochure was assessed using five
multiple-choice questions concerning:
identification of AEs; management and
treatment of induced cranial nerve palsies;
identification of patients at risk of
cardiotoxicities; management and treatment of
Stevens–Johnson syndrome/toxic epidermal
necrolysis; and AE-reporting procedures if such
rare risks were identified.
To encourage the completion of all survey
questions, partial completion of the survey or
failure to pass (pass defined as correct response
to at least four out of five questions answered)
on the first attempt resulted in a prompt to
repeat the unanswered or incorrectly answered
questions.
To minimize bias in responses, the HCPs
who were sent the survey had no face-to-face
visits or contact with the sponsor’s
representatives to specifically discuss the HCP
brochure or survey; in addition, survey
questions were designed to be non-leading.
The survey was designed so that it could be
completed from any electronic device.
Between September and October 2014, HCPs
were sent an email with an invitation to
participate in the online survey. The first
invitation was sent 1 week after distribution of
the HCP brochure, and reminders were sent to
non-responders once a week over a 3-week period.
HCPs were offered a small monetary incentive to
complete the survey. Unique IDs assigned to
responders ensured that each respondent could
participate only once in the survey.
Study Outcomes
The primary aims of the study were to:
(a) monitor and (b) assess the effectiveness of
the educational brochure in accordance with
the medicine’s proposed risk minimization
program for Australia. The process used was
similar to that outlined by Banerjee et al. [1],
and based on the European Medicines Agency
(EMA) Good Pharmacovigilance Practices (GVP)
Module XVI [4] and the Council for
International Organization of Medical Sciences
(CIOMS) IX report [5]. The study effectively
assessed the first three levels of the Banerjee
model using two main process indicators:
awareness, which measured the coverage and
awareness of the educational brochure across
the target population of interest; and
understanding/knowledge, which assessed target
respondents’ understanding of information
contained in the brochure using five
predefined multiple-choice questions.
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For the purpose of the study, the educational
brochure was considered to be a valid method
for risk reduction if a predefined C80% of HCP
respondents answered C80% (four out of five)
questions from Part 2 of the survey correctly.
Data Analysis
The data were summarized and analyzed
descriptively based on the total number of
HCPs who were sent the educational brochure
to evaluate the defined process indicators.
Awareness was assessed by the number and
percentage of HCPs responding to the survey,
the number and percentage of HCPs confirming
receipt of the educational brochure, and the
number and percentage who had confirmed
reading the brochure. Understanding/knowledge
was assessed by the number and percentage of
HCP responders who passed the survey;
assessment of pass rate [percentage of HCPs
who responded and passed the survey (defined
as correctly responded to at least four out of five
questions in Part 2 of the survey)]; and number
and percentage of HCPs who correctly answered
each of the questions in Part 2 of the survey.
Results from respondents who had received the
brochure were also compared with that from
respondents who had not received the brochure
(obtained from information collected from Part
1 of the survey).
RESULTS
The final database included 574 HCPs who were
sent the educational brochure. Seven HCPs in
the database with undeliverable or disabled
email addresses and two with out-of-office
responses were removed from the study
population, giving a final effective sample of
565 HCPs. Of these, 121 (21.4%) responded to
the survey. The profile of the respondent sample
is shown in Table 1. Overall, the respondent
sample reflected the structure of the
original database, only with a slightly higher
proportion of oncology pharmacists (Fig. 1).
The majority of survey respondents had
previously prescribed or dispensed
nab-paclitaxel (overall: 95.0%; oncology
pharmacists: 95.0%; hemato-oncologists: 100%;
medical oncologists: 94.9%).
Awareness
In all, 88 (72.7%) respondents said they had
received the educational brochure (Fig. 2). More
oncology pharmacists (87.5%) said they had
received the brochure than did oncology
clinicians (65.4%).
Overall, 70.2% of the total survey
participants (i.e., including those who had
received and those who had not received)
stated they had read the educational brochure.
Of those respondents who reported having
received the educational brochure, a high
proportion stated they had read it (95.5%),
with similar findings in oncology pharmacists
(97.1%) and oncology clinicians (94.3%). All
other respondents who received the educational
brochure stated that they intended to read it. Of
those recipients who had read the educational
brochure, the majority (65.9%) stated that they
had scanned the main points, and more than a
quarter (29.5%) stated that they had read it in
detail (Fig. 2).
Understanding
Overall, 83.5% of all HCPs who responded to
the survey answered at least four out of five
questions correctly, with similar results in
oncology pharmacists (90.0%) and oncology
clinicians (80.2%). However, significantly more
HCPs who received the brochure answered four
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or five questions correctly compared with HCPs
who did not receive the brochure (93.2% vs
57.6%, respectively; P = 0.000003).
In the multiple-choice questions comprising
Part 2 of the survey, each of the individual five
survey questions, designed to assess the
understanding of information in the brochure,
was answered correctly by at least 76.0% of the
total respondent sample; however, for the
majority of questions, the proportion of
respondents answering correctly was
significantly higher in those who had received
the educational brochure compared with those
who did not (Fig. 3).
DISCUSSION
The results of this study provide important
insights into the effectiveness of an educational
brochure as a post-marketing risk minimization
Table 1 Sample proﬁle, n (%)
Medical oncologists Hemato-oncologists Oncology pharmacists Total
New South Wales 24 1 9 34
Victoria 29 0 13 42
Queensland 13 0 3 16
South Australia 3 0 4 7
Western Australia 5 0 7 12
Tasmania 3 1 4 8
Northern Territory 1 0 0 1
Australian Capital Territory 1 0 0 1
Total 79 2 40 121
Fig. 1 Survey participant demographics. (a) Job role,
(b) location. ACT Australian Capital Territory, NSW
New South Wales, NT Northern Territory, QLD
Queensland, SA South Australia, TAS Tasmania, VIC
Victoria, WA Western Australia
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strategy for the communication of information
on new rare and important
treatment-associated AEs. Almost
three-quarters of those HCPs who responded
acknowledged receipt of the educational
brochure, and almost all who acknowledged
receipt reported that they had read the
brochure. This suggests that there is a high
likelihood that for clinicians like those who
responded to the survey, this educational
brochure will be read—provided it can be
successfully distributed to health-care
professionals. The efficacy of the educational
brochure in raising awareness of new rare and
important AEs was demonstrated by the fact
that a significantly higher proportion of
Fig. 2 Respondents’ awareness of the communication
Fig. 3 Proportion of HCPs who answered/understood the survey questions correctly (a) overall, (b) for each question.
HCP health-care professionals
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responders who received the brochure were able
to correctly answer survey questions compared
with HCPs who did not receive it, with a
significantly higher proportion of responders
who had received the brochure attaining the
predefined pass rate compared with those who
had not received the brochure.
Evaluation of the effectiveness of any drug
risk minimization tool is important to
understand the effectiveness of the strategy;
however, to date, there is only minimal
guidance available [4–6]—and even this
guidance does not provide detailed
methodology for evaluation of risk
minimization activities. To our knowledge,
this is the first study to successfully measure
the effectiveness of an educational brochure in
communicating information on new rare and
important treatment-associated AEs to HCPs.
The evaluation of the effectiveness of risk
minimization interventions is a pivotal part of
continuous pharmacovigilance, and an analysis
of interventions implemented—and whether
they have been successful in reducing risk—is
crucial [7]. While proof of risk reduction is
pivotal to any risk management strategy [7], it
is beyond the scope of this study. However, proof
of implementation is an equally important step
in risk management strategies and is necessary if
we are to assess subsequent data regarding the
reduction of risk. Should a particular strategy fail
to reduce risk, assessment of implementation
will help determine whether this failure arose at
the implementation stage, or was the result of a
conceptual error in the strategy itself [7].
Pharmaceutical companies primarily
communicate risk through labeling tools such
as the prescribing information, package insert,
patient information leaflet, and the carton [2].
However, the efficacy of such approaches has
been poorly investigated, and recent research
has raised concerns over the effectiveness of
some of these methods [2]. The evidence behind
the effectiveness of printed materials in
disseminating information and influencing
HCP behavior is inconclusive. A recent
Cochrane review looked at a range of studies
evaluating the impact of the distribution of
printed educational materials on HCP practice
and patient outcomes [3]. This analysis
included studies using a wide range of
distribution techniques including personally
addressed communications, communications
delivered via mass mailings, and passively
delivered communications utilizing broader
communication channels (e.g.,
printable documents available on the Internet,
mass media). The conclusion of the study was
that printed educational materials, when used
alone and compared with no intervention, have
a small beneficial effect on professional practice
outcomes [3]. The Cochrane analysis included
only those studies assessing the impact of
published or printed recommendations for
clinical care, such as clinical practice
guidelines, monographs, health authority
guidelines and recommendations, and
publications in peer-reviewed journals. While
there are a number of studies focusing on the
impact of these publications on clinical
practice, there are fewer addressing the value
of more focused, issue-driven printed
educational materials in raising awareness of
specific clinical issues. A Canadian study
investigating physician knowledge of the AEs
of treatment with androgen-deprivation
therapy found that a significant proportion
(82%) of primary care providers would use
educational resources to increase their
knowledge of AEs if they were available (52%
and 32% preferred continued medical
education and educational pamphlets,
respectively) [8]. A study investigating the
efficacy of a hepatitis C virus education
174 Adv Ther (2016) 33:167–177
program in Victoria, Australia, found that HCPs
who read a post-program feedback brochure
were more likely to correctly identify key issues
in hepatitis C risk, prognosis, and management
[9]. An Australian study investigating whether
the distribution of electronic newsletters,
containing case studies and lessons learned on
deaths in residential care, could influence HCPs
found that around half of the respondents to
the survey reported changing their professional
practice as a result of reading the communique´s,
with around one-fifth agreeing they would not
have made the changes if they had not read the
publication [10].
Our study has a number of strengths. The
survey performed in this study was in line with
United States Food and Drug Administration
(FDA)-recommended practice for survey
methodologies used to assess the effectiveness
of risk evaluation and mitigation strategies [6].
Key risk messages were identified, and the
questionnaire developed to target these key
risk messages. By using the STA database, we
were able to target relevant HCPs (i.e., those
who used, prescribed, and/or dispensed the
target medicine) and provide a representative
sample of the entire population of product
users. This along with avoidance of the use of
leading questions limited bias. The short length
of the survey, which was easy to complete using
any electronic device, minimized the burden
imposed on the survey participants. Shorter and
simpler documents have the potential to
facilitate more effective and efficient uptake of
key information, given that HCPs may not have
time to screen and appraise new scientific
literature [3], or to read longer formal
documents such as full prescribing
information in detail.
In addition, by asking the question ‘‘Did you
read the brochure: Yes or No?’’ we were able to
provide a comparator group which is often
lacking in studies of this type. This was a
prospective study with a predefined measure
of success (pass rate). Finally, we consulted with
and received input from the regulator in the
design of the study and outcomes.
There are limitations inherent to the nature
of this study which should be considered. In
common with many other survey-based studies,
responder bias (only around one-fifth of HCPs
responded to the survey) may have influenced
the results of the current study, and the results
may not be generalizable to a wider population
or to other clinical areas. HCPs, particularly
clinicians, generally show a low rate of response
to surveys—and the rate of response has
declined over recent decades [11–13].
However, and despite these limitations,
surveys are an efficient, inexpensive, and
flexible means of collecting information from
a large pool of respondents and an important
means of assessing and evaluating information
dissemination [12, 13]. For the current study,
the results of the survey were accepted by the
TGA to demonstrate the effectiveness of the
educational brochure as an enhanced risk
minimization activity for nab-paclitaxel, and it
was agreed that repeat distribution of the
educational brochure was not necessary.
CONCLUSIONS
Our study suggests that targeted educational
brochures are a useful communication
mechanism for clinicians like those who
responded to the survey to raise HCP
awareness of new rare and important AEs; they
are also effective in sharing information on how
these AEs can be best managed and on the
importance and means of reporting AEs. Such
brochures may be of particular use as part of risk
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minimization strategies in rapidly changing
fields such as oncology, where HCPs need to
deal with increasing complex medicines and
protocols to treat cancers.
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